Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression
Author:
Funder
Taiwan Ministry of Science and Technology
Changhua Christian Hospital
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference34 articles.
1. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version);Hammond;Arch. Pathol. Lab. Med.,2010
2. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer;Colleoni;J. Clin. Oncol.,2001
3. Advances in adjuvant endocrine therapy for postmenopausal women;Lin;J. Clin. Oncol.,2008
4. Acquired resistance of ER-positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through posttranslational downregulation of c-FLIP;Piggott;Clin. Cancer Res.,2018
5. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years;Pan;New Engl. J. Med.,2017
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2− breast cancer: an umbrella review;Journal of Cancer Research and Clinical Oncology;2024-01-19
2. Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure;World Journal of Clinical Cases;2024-01-06
3. USP7 Induces Chemoresistance in Triple-Negative Breast Cancer via Deubiquitination and Stabilization of ABCB1;Cells;2022-10-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3